<DOC>
	<DOC>NCT01065012</DOC>
	<brief_summary>Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).</brief_summary>
	<brief_title>Treatment of Erectile Dysfunction - Long Term Safety and Efficacy</brief_title>
	<detailed_description>Patients completing the double-blind phase will be entered into Study 01409 at the intermediate dose. Up and down dose adjustments will be allowed.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Subject has completed Study PR01209 or PR01309 Continues in a stable monogamous relationship with a consenting female partner who is at least 19 years of age. Partner is not pregnant or lactating Symptomatic coronary artery disease, myocardial infarction or cardiac surgical procedure. Cardiac arrhythmias requiring antiarrhythmic treatment Symptomatic congestive heart failure Taking nitrate medication in any form Uncontrolled diabetes (HbA1c â‰¥ 13%) Hypersensitivity to phosphodiesterase type 5 (PDE5) inhibitors</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>